{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:36:28Z","timestamp":1761514588856},"reference-count":22,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"Supl. 1","content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["biomedica"],"abstract":"<jats:p>Introducci\u00f3n. La satisfacci\u00f3n y el conocimiento del cambio de tenofovir por tenofovir-alafenamida en pacientes con HIV no se han estudiado a\u00fan. Estos dos par\u00e1metros se relacionan con mejores resultados en salud y, por lo tanto, es importante medirlos durante la pr\u00e1ctica cl\u00ednica habitual.Objetivo. Evaluar el grado de conocimiento y satisfacci\u00f3n de los pacientes positivos para HIV ante el cambio de tratamiento antirretroviral con rilpivirina, emtricitabina y tenofovir (RPV-FTC-TDF) por rilpivirina, emtricitabina y tenofovir-alafenamida (RPV-FTC-TAF).Materiales y m\u00e9todos. Se llev\u00f3 a cabo un estudio prospectivo en un hospital de tercer nivel entre los meses de septiembre y noviembre de 2018. Se incluyeron pacientes previamente tratados con RPV-FTC-TDF que acud\u00edan por segunda vez a consulta para recibir el tratamiento con RPV-FTC-TAF. La satisfacci\u00f3n y el grado de conocimiento se analizaron mediante nueve preguntas, usando una escala de tipo Likert de 5 puntos para evaluar el grado de acuerdo.Resultados. Se incluyeron 116 pacientes en el estudio. El 75 % de ellos se mostr\u00f3 satisfecho con el cambio y se consider\u00f3 que el 64 % conoc\u00eda lo que implicaba. Los pacientes j\u00f3venes se mostraron menos satisfechos con el modo en que se les explic\u00f3 el cambio (p=0,0487). Los pacientes estaban mejor informados sobre las ventajas renales (85 % de conocimiento) y \u00f3seas (82 %) de la nueva medicaci\u00f3n, que sobre sus inconvenientes para el perfil lip\u00eddico (40 %).Conclusiones. En general, los pacientes se mostraron satisfechos con el cambio de medicaci\u00f3n y conoc\u00edan la posolog\u00eda del medicamento y las ventajas de la tenofovir-alafenamida frente al tenofovir, pero no sus posibles efectos adversos.<\/jats:p>","DOI":"10.7705\/biomedica.4989","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T21:32:34Z","timestamp":1590615154000},"page":"132-138","update-policy":"http:\/\/dx.doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Grado de satisfacci\u00f3n y conocimiento de pacientes positivos para HIV ante el cambio de tenofovir a tenofovir-alafenamida en tratamientos con emtricitabina y rilpivirina"],"prefix":"10.7705","volume":"40","author":[{"given":"Manuel","family":"V\u00e9lez-D\u00edaz-Pallar\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Gramage-Caro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Rodr\u00edguez-Sagrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Montero-Llorente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Bermejo-Vicedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4444","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"97906","doi-asserted-by":"crossref","unstructured":"Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials ompared with the general population. AIDS. 2013;27:973-9. https:\/\/doi.org\/10.1097\/QAD.0b013e32835cae9c","DOI":"10.1097\/QAD.0b013e32835cae9c"},{"key":"97907","unstructured":"Casado JL. Renal and bone toxicity with the use of tenofovir: Understanding at the end. AIDS Rev. 2016;18:59-68."},{"key":"97908","doi-asserted-by":"crossref","unstructured":"De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1-7. https:\/\/doi.org\/10.1016\/j.bcp.2016.04.015","DOI":"10.1016\/j.bcp.2016.04.015"},{"key":"97909","doi-asserted-by":"crossref","unstructured":"Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: A randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3:e158-65. https:\/\/doi.org\/10.1016\/S2352-3018(16)00024-2","DOI":"10.1016\/S2352-3018(16)00024-2"},{"key":"97910","doi-asserted-by":"crossref","unstructured":"Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606-15. https:\/\/doi.org\/10.1016\/S0140-6736(15)60616-X","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"97911","doi-asserted-by":"crossref","unstructured":"Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018;19:724-33. https:\/\/doi.org\/10.1111\/hiv.12664","DOI":"10.1111\/hiv.12664"},{"key":"97912","doi-asserted-by":"crossref","unstructured":"Lee SS, Havens JP, Sayles HR, O\u2019Neill JL, Podany AT, Swindells S, et al. A pharmacist-led medication switch protocol in an academic HIV clinic: Patient knowledge and satisfaction. BMC Infect Dis. 2018;18:310. https:\/\/doi.org\/10.1186\/s12879-018-3226-2","DOI":"10.1186\/s12879-018-3226-2"},{"key":"97913","doi-asserted-by":"crossref","unstructured":"Dang BN, Westbrook RA, Black WC, Rodr\u00edguez-Barradas MC, Giordano TP. Examining the link between patient satisfaction and adherence to HIV care: A structural equation model. PloS One. 2013;8:e54729. https:\/\/doi.org\/10.1371\/journal.pone.0054729","DOI":"10.1371\/journal.pone.0054729"},{"key":"97914","doi-asserted-by":"crossref","unstructured":"McNicholl IR, Gandhi M, Hare CB, Greene M, Pierluissi E. A pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older HIV positive patients. Pharmacotherapy. 2017;37:1498-506. https:\/\/doi.org\/10.1002\/phar.2043","DOI":"10.1002\/phar.2043"},{"key":"97915","doi-asserted-by":"crossref","unstructured":"Schafer JJ, Gill TK, Sherman EM, McNicholl IR. ASHP Guidelines on pharmacist involvement in HIV care. Am J Health Syst Pharm. 2016;73:468-94. https:\/\/doi.org\/10.2146\/ajhp150623","DOI":"10.2146\/ajhp150623"},{"key":"97916","doi-asserted-by":"crossref","unstructured":"Bowling A, Rowe G, Lambert N, Waddington M, Mahtani KR, Kenten C, et al. The measurement of patients\u2019 expectations for health care: A review and psychometric testing of a measure of patients\u2019 expectations. Health Technol Assess. 2012;16:1-509. https:\/\/doi.org\/10.3310\/hta16300","DOI":"10.3310\/hta16300"},{"key":"97917","unstructured":"Cantillana-Su\u00e1rez M de G, Manzano-Garc\u00eda M, Robustillo-Cort\u00e9s M de LA, Morillo-Verdugo R. Evaluation of HIV+ patients experience with pharmaceutical care based on AMOmethodology. Farm Hosp. 2018;42:200-3. https:\/\/doi.org\/10.7399\/fh.10947"},{"key":"97918","doi-asserted-by":"crossref","unstructured":"Umeokonkwo CD, Aniebue PN, Onoka CA, Agu AP, Sufiyan MB, Ogbonnaya L. Patients\u2019 satisfaction with HIV and AIDS care in Anambra State, Nigeria. PLoS One. 2018;13:e0206499. https:\/\/doi.org\/10.1371\/journal.pone.0206499","DOI":"10.1371\/journal.pone.0206499"},{"key":"97919","doi-asserted-by":"crossref","unstructured":"Clay PG, Yuet WC, Moecklinghoff CH, Duchesne I, Tronczy\u0144ski KL, Shah S, et al. A metaanalysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15:17. https:\/\/doi.org\/10.1186\/s12981-018-0204-0","DOI":"10.1186\/s12981-018-0204-0"},{"key":"97920","doi-asserted-by":"crossref","unstructured":"Murray M, Pulido F, Mills A, Ramgopal M, LeBlanc R, Jaeger H, et al. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. HIV Res Clin Pract. 2019:20:111-122. https:\/\/doi.org\/10.1080\/25787489.2019.1661696","DOI":"10.1080\/25787489.2019.1661696"},{"key":"97921","doi-asserted-by":"crossref","unstructured":"George EC, Bucciardini R, Richert L, Dedes N, Fragola V, Nieuwkerk P, et al. Patient reported outcomes in first-line antiretroviral therapy: Results from NEAT001\/ANRS143 trial comparing darunavir\/ritonavir in combination with tenofovir\/emtricitabine or raltegravir. J Acquir Immune Defic Syndr. 2018;79:519-26. https:\/\/doi.org\/10.1097\/QAI.0000000000001844","DOI":"10.1097\/QAI.0000000000001844"},{"key":"97922","doi-asserted-by":"crossref","unstructured":"Moreno-Montoya J, Barrag\u00e1n AM, Mart\u00ednez M, Rodr\u00edguez A, Gonz\u00e1lez AC. Calidad de vida y percepci\u00f3n de apoyo social en personas con HIV en Bogot\u00e1, Colombia. Biom\u00e9dica. 2018;38:577-85. https:\/\/doi.org\/10.7705\/biomedica.v38i4.3819","DOI":"10.7705\/biomedica.v38i4.3819"},{"key":"97923","doi-asserted-by":"crossref","unstructured":"N\u00e1fr\u00e1di L, Nakamoto K, Schulz PJ. Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. PloS One. 2017;12:e0186458. https:\/\/doi.org\/10.1371\/journal.pone.0186458","DOI":"10.1371\/journal.pone.0186458"},{"key":"97924","doi-asserted-by":"crossref","unstructured":"Jones D, Cook R, Rodr\u00edguez A, Waldrop-Valverde D. Personal HIV knowledge, appointment adherence and HIV outcomes. AIDS Behav. 2013;17:242-9. https:\/\/doi.org\/10.1007\/s10461-012-0367-y","DOI":"10.1007\/s10461-012-0367-y"},{"key":"97925","doi-asserted-by":"crossref","unstructured":"Kusch MK, Haefeli WE, Seidling HM. How to meet patients\u2019 individual needs for drug information - a scoping review. Patient Prefer Adherence. 2018;12:2339-55. https:\/\/doi.org\/10.2147\/PPA.S173651","DOI":"10.2147\/PPA.S173651"},{"key":"97926","doi-asserted-by":"crossref","unstructured":"Dekkers CC, Westerink J, Hoepelman AI, Arends JE. Overcoming obstacles in lipid lowering therapy in patients with HIV - a systematic review of current evidence. AIDS Rev. 2018;20:205-19. https:\/\/doi.org\/10.24875\/AIDSRev.18000016","DOI":"10.24875\/AIDSRev.18000016"},{"key":"97927","doi-asserted-by":"crossref","unstructured":"Jose J, AlHajri L. Potential negative impact of informing patients about medication side effects: A systematic review. Int J Clin Pharm. 2018;40:806-22. https:\/\/doi.org\/10.1007\/s11096-018-0716-7","DOI":"10.1007\/s11096-018-0716-7"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/4989\/4477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/4989\/4477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T19:51:12Z","timestamp":1590781872000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/4989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":22,"journal-issue":{"issue":"Supl. 1","published-online":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.4989","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"value":"2590-7379","type":"electronic"},{"value":"0120-4157","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]},"assertion":[{"value":"2020-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Original articles","name":"content_type","label":"Content Type"}]}}